Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-5172 + MK-8742 for chronic hepatitis C genotype 1 in patients with advanced chronic kidney disease
NL-OMON40914Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of grazoprevir and verubecestat in chronic hepatitis C (CHC) and chronic kidney disease (CKD) (3 arms), sponsored by Merck & Co. Primary endpoints: Sustained virologic response in immediate treatment and intensive PK groups and Safety and tolerability versus placebo. Started Jun 2014; status: active, not recruiting.
02
Drugs
grazoprevirverubecestat
03
Conditions
chronic hepatitis C (CHC)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON40914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40914.